NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS

NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "RIVASTIGMINE TRANSDERMAL PATCH"

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH BENMELSTOBART INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA WAS PRESENTED AT ESMO 2024

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WAS PRESENTED AT ESMO 2024

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT 2024 CSCO

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA